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Abstract
Background: During the last years the analysis of microRNA expression patterns has led to
completely new insights into cancer biology. Furthermore, these patterns are a very promising tool
for the development of new diagnostic and prognostic markers. However, most human tumour
samples for which long term clinical records are available exist only as formalin-fixed paraffin-
embedded specimens. Therefore, the aim of this study was to examine the feasibility of microRNA
profiling studies in routinely processed formalin-fixed paraffin-embedded human breast cancer
specimens using fluorescence labelled bead technology.
Results: A statistically highly significant correlation (Spearman r: 0.78 – 0.90, p < 0.0001) was
observed for the expression of 319 microRNAs in routinely processed FFPE breast cancer
specimens and paired fresh frozen tissue samples (n = 5). Results were confirmed in a larger series
analyzing a selection of 10 microRNAs reported to be deregulated in breast cancer (n = 12). The
expression pattern of 3 microRNAs was independently validated in this cohort using real-time RT-
PCR technology.
Conclusion:  Comprehensive microRNA expression patterns can be reliably derived from
routinely processed FFPE breast cancer specimens using fluorescence labelled bead technology.
Background
Formalin-Fixed, Paraffin-Embedded (FFPE) tissue sam-
ples represent an invaluable source for the study of
human disease. Millions of blocks are archived world
wide with corresponding well-documented clinical histo-
ries and histopathological reports. The potential value of
these archives for retrospective molecular studies has been
well recognized [1]. However, the feasibility of every new
technology for the molecular analysis of archival FFPE
material has to be carefully evaluated using corresponding
fresh-frozen material from the very same tissue sample.
The analysis of microRNA expression patterns in human
tumour specimens promises to provide completely new
insights into tumour biology. In addition, it may contrib-
ute to the development of new diagnostic or predictive
markers [2,3]. But the vast majority of published studies
rely on the analysis of fresh-frozen tissue specimens.
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Therefore, several studies have addressed the question of
microRNA expression profiling in FFPE samples. How-
ever, the number of routinely processed clinical speci-
mens analyzed is altogether very low [4-9]. In some
studies no fresh-frozen and corresponding archival
human material is analyzed [6] or only from a single
human tissue specimen [4,5]. All these studies made use
of PCR- or array-based methodologies
The quantification of microRNA expression levels using
LNA probes coupled to fluorescence labelled beads offers
several advantages: No amplification step is required
which may introduce a potential bias and the hybridiza-
tion of probes and target sequences takes place in a homo-
geneous system [10].
So far, no systematic comparison of microRNA profiles
obtained from fresh-frozen and corresponding FFPE sam-
ples using the fluorescence labelled bead technology is
described.
In this study we examined the expression pattern of 319
microRNAs in routinely processed formalin-fixed paraf-
fin-embedded breast cancer specimens and paired fresh-
frozen specimens from the very same tumours. For this
purpose the fluorescence labelled bead technology from
Luminex (Austin, Texas, USA) was employed.
Results
Quality control of RNA and recovery rate of microRNA
The integrity and quality of the RNA preparations was
analysed using the microcapillary fluid device form Agi-
lent (Agilent 2100 Bioanalyzer). The mean "RNA integrity
number" (RIN)[11] for all 12 fresh-frozen breast cancer
specimens was 7.65 (+/- 0.93, range: 5.2 – 8.7) represent-
ing quite faithfully the range of routinely processed tissue
specimens with high but not perfect quality of the RNA.
The highly fragmented RNA from the corresponding for-
malin-fixed paraffin-embedded tissue samples displayed
a mean RIN of 2.26 (+/- 0.28, range: 1.6 – 2.5).
The mean fluorescence intensity, the highest fluorescence
intensity, and the sum of all fluorescence intensities were
not reduced in any of the FFPE samples compared to the
corresponding fresh-frozen sample (data not shown).
Therefore, no reduction in microRNA recovery due to for-
malin-fixation was observed.
Comprehensive microRNA expression profiling in paired 
fresh-frozen and formalin-fixed specimens
The expression level of 319 microRNAs (FlexMir panel
version 8 from Luminex) was measured in 5 fresh-frozen
breast cancer specimens and corresponding formalin-
fixed paraffin-embedded tissue samples from the very
same tumour. The measurements showed a very good cor-
relation for all 5 paired samples (Fig. 1 and Additional
files 1 and 2). The Spearman rank correlation factors were
between 0.6888 and 0.8358 (mean: 0.789) with p-values
smaller than 0.0001 for all sample pairs (two-tailed test).
Excluding all signals below a background corrected mean
fluorescence intensity of less than 100 (arbitrary units of
the machine) increased the correlation factors up to
0.8978 (range: 0.7789 – 0.8978, mean: 0.833, see Fig. S1).
Expression of 10 selected microRNAs in paired fresh-
frozen and formalin-fixed specimens
10 individual microRNAs were selected from the literature
as most frequently deregulated in primary human breast
cancer (as at December 2007, see Table 1, for a recent
overview see also [12]).
The expression level of these 10 microRNAs was measured
in a series of 12 paired fresh-frozen and FFPE samples (see
Fig. 2). Five of these samples were already used for the
profiling of 319 microRNAs (see Fig. 1). For eight samples
a statistically significant correlation was observed (range
of correlation factors: 0.72 to 0.81, mean: 0.77, p < 0.05)
whereas for four samples only a trend towards statistical
significance (r = 0.41 to 0.62) was observed (The individ-
ual p-values for all 12 sample pairs are given in Additional
files 3 and 4.). Also, the overall pattern of expression is
similar in the four samples without statistical significant
correlation. The same microRNAs are up- or down-regu-
lated; only the extent of regulation is different (see Addi-
tional files 3 and 4).
Validation using real-time RT-PCR methodology
The expression level of three microRNAs (miR-10b, miR-
145, miR-21) was measured in all samples (12 fresh fro-
Comparison of expression levels of 319 microRNAs in  paired fresh-frozen and formalin-fixed paraffin-embedded  human breast cancer specimens Figure 1
Comparison of expression levels of 319 microRNAs 
in paired fresh-frozen and formalin-fixed paraffin-
embedded human breast cancer specimens. The com-
plete data set for BrC1 – BrC5 is shown in Additional files 1 
and 2.
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zen and 12 FFPE) using the stem-loop primer real-time
PCR methodology from ABI (Darmstadt, Germany).
Overall, the expression pattern (miR-10b versus miR-145
and miR-10b versus miR-21) obtained with this com-
pletely different technique is quite similar: The expression
level of miR-145 is only slightly higher than the expres-
sion level of miR-10b whereas miR-21 is much stronger
expressed than miR-10b (see Table 2).
However, the extent of overexpression of microRNA 21
relative to miR-10b was approx. four fold higher using
real-time PCR (mean: approx. 170-fold) than using the
bead-based methodology (mean: approx. 40-fold).
Discussion
The systematic comparison of paired fresh-frozen and for-
malin-fixed paraffin-embedded tissue specimens from the
very same tumour shows that reliable microRNA expres-
sion pattern can be obtained from routinely processed
breast cancer specimens using the fluorescence-labelled
bead-based technology from Luminex. However, a disad-
vantage of the current microRNA profiling methodology
from Luminex is the requirement of quite large amounts
of total RNA (2.5 – 5 μg) which is clearly not available for
every interesting case.
The much stronger overexpression of miR-21 as measured
by real-time PCR in comparison to the bead-based meth-
odology could be due to slight differences in amplifica-
tion efficiencies for these two microRNAs. These slight
differences in efficiency create a considerable difference in
expression level after 25 or 30 cycles due to the exponen-
tial nature of the amplification process. Additional
sources of differences between the methods compared are
the completely different RNA processing (cDNA synthesis
versus direct biotin-labelling) and differences in analytical
sensitivity (which is higher for real-time PCR). But never-
theless, the overall pattern is the same using both tech-
niques.
Leaving out all signals below 100 arbitrary units improved
the correlation quite significantly for three out of five sam-
ples, clearly indicating that most of the variability
between paired samples are due to fluctuations of the sig-
nals of very weekly expressed microRNAs.
Nelson et al. [4] analysed in their pioneering study using
their newly developed assay ("RAKE") among other sam-
ples a single pair of fresh-frozen and formalin-fixed mate-
rial from the same tumour (from an anaplastic
oligodendroglioma). To the best of our knowledge this
represents the very first description of the feasibility of
large-scale microRNA profiling in archival samples. A vis-
ual inspection of Figure 5 from Nelson et al. gives the
impression of quite high concordance between the fresh-
frozen and the formalin-fixed sample. However, a formal
statistical analysis is not presented and only a single
tumour specimen was analyzed.
Table 1: microRNAs deregulated in human breast cancer
miR references
10b [16,17]
17-5p [18]
21 [16,19-21]
27a [22,23]
125a [24,19,25]
125b [16,19,24,25]
145 [16,19]
155 [16,19]
200c [24,26]
206 [27]
Comparison of expression levels of 10 selected microRNAs  (see Table 1 for selection) in paired fresh-frozen and forma- lin-fixed paraffin-embedded human breast cancer specimens Figure 2
Comparison of expression levels of 10 selected 
microRNAs (see Table 1 for selection) in paired 
fresh-frozen and formalin-fixed paraffin-embedded 
human breast cancer specimens. The individual expres-
sion levels were normalized to the mean of the four normali-
zation controls included by Luminex (snoRNAs C/D box 
U13, C/D box U6, C/D box 2, C/D box 6). The complete 
data set for BrC1 – BrC12 is shown in Additional files 3 and 
4.
BrC1
hsa-miR-10b
hsa-miR-125a
hsa-miR-125b
hsa-miR-145
hsa-miR-155
hsa-miR-17-5p
hsa-miR-206
hsa-miR-21
hsa-miR-27a
hsa-miR200c
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r = 0.79
p = 0.009
Table 2: Comparison of quantitative real-time PCR results with 
fluorescence labelled bead technology. 
miR145/miR10b miR21/miR10b
qPCR-FFPE 1.3 +/- 0.6 189 +/-137
qPCR-kryo 0.9 +/- 0.4 143 +/- 79
beads-FFPE 2.4 +/- 1.3 19 +/- 6.6
beads-kryo 5.5 +/- 3.1 62 +/- 49
Mean expression ratios for three selected microRNAsBMC Biotechnology 2008, 8:90 http://www.biomedcentral.com/1472-6750/8/90
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Li et al. [6] published a comparison of microRNA profiles
from snap-frozen cell pellets and formalin-fixed paraffin-
embedded cell pellets from an immortalized cell line. The
expression level of 160 microRNAs was measured using
quantitative real-time PCR and a very good correlation
was observed. However, this very well controlled situation
does not reflect the routine process with all its uncertain-
ties and variability. Also, the fixation process of a tissue
sample is quite different from the fixation of a cell pellet.
Xi et al. [7] studied 254 microRNAs using an LNA-probe
array. Analyzing mouse liver tissue the authors found a
good correlation between fresh-frozen and formalin-fixed
samples (r2 = 0.86 – 0.89). However, no corresponding
pairs of routinely processed human tissue samples were
analyzed. Only a single archival human colon cancer spec-
imen for which no corresponding fresh-frozen material
was available was analyzed.
Wang et al. [8] mention at the end of the results section
the analysis of 5 pairs of fresh-frozen and formalin-fixed
breast tumours using microarray technology and report
correlation coefficients similar to those described in this
study (r = 0.443 – 0.927). However, they do not show any
primary data and do not provide any data about data val-
idation using a different method.
Lawrie et al. [5] showed in a supplementary figure the
analysis of corresponding fresh-frozen and formalin-fixed
material from a single lymph node sample using a pub-
lished microRNA array. Visual inspection of the figure
shows a good correlation but no formal statistical analysis
is provided by the authors.
The recently published study from Hoefig et al. [9] repre-
sents so far the largest direct comparison of microRNA
expression patterns obtained from fresh-frozen and corre-
sponding FFPE samples (4 liver and 7 tonsil specimens).
The authors used the real-time PCR technology from
Applied Biosystems for the analysis of 157 microRNAs.
According to the authors, the variance caused by formalin
fixation was much smaller than the variance introduced
by biological differences (liver versus tonsils). Since the
careful data analysis is exclusively based on threshold
cycle (CT) values and the shift in CT values, a direct com-
parison with the correlation coefficients obtained by us
using a different methodology is not possible. However,
both technical approaches seem to provide reliable data.
Finally, the evaluation of different microRNA isolation
procedures recently published by Doleshal et al. [13], con-
tains also the comparison of microRNA expression levels
in paired fresh frozen and formalin-fixed paraffin-embed-
ded specimens using real-time PCR-based methodology,
but only for three individual microRNAs.
Conclusion
The data presented in this study convincingly show that
routinely processed human FFPE tissue specimens are
suitable for large-scale as well as small-scale microRNA
profiling projects using fluorescence labelled bead tech-
nology. Therefore, this methodology can now be used for
large retrospective studies utilizing stored archival FFPE
samples together with the corresponding clinical and his-
topathological records.
Note added in proof:
During the revision of this manuscript Zhang et al. pub-
lished the comparison of microRNA expression patterns
from fresh-frozen and corresponding FFPE lymph node
specimens (n = 7) using the Agilent microarray platform
(Agilent, Santa Clara, CA). [14] These authors also found
a very good correlation between measurements of
matched fresh-frozen and FFPE samples.
Methods
Patient samples
12 fresh frozen breast cancer specimens and correspond-
ing formalin-fixed paraffin-embedded tissue samples
from the very same tumours were retrieved from the
archives of the Institute of Pathology, Medizinische Hoch-
schule Hannover in an anonymous fashion following the
guidelines of the local Ethics committee. Tumour cell con-
tent was controlled on an HE stained serial section and
above 80% for all cases.
RNA isolation
Total RNA was isolated from fresh-frozen specimens using
TRIZOL™ reagent (Invitrogen, Karlsruhe, Germany) fol-
lowing the protocol supplied by the manufacturer. Isola-
tion of total RNA from FFPE specimens was performed as
described previously. [15] Following the recommenda-
tions from Luminex Inc. no microRNA enrichment was
performed.
RNA quality control
An aliquot of 150 ng of every RNA preparation was
checked for integrity in an Agilent 2100 Bioanalyzer (Agi-
lent Technologies, Waldbronn, Germany). Sample prepa-
ration and analysis were performed following the
manufacturer's instruction.
microRNA measurement using fluorescence labelled beads
Quantification of microRNAs hybridized to fluorescence
labelled beads was performed with a BioPlex 200™ from
Biorad (Bio-Rad Laboratories GmbH, München, Ger-
many) using the software Luminex IS™, version 2.3 from
Luminex (Austin, Texas, USA). All beads coated with LNA
probes complementary to mature microRNAs were pur-
chased from Luminex (Austin, Texas, USA).BMC Biotechnology 2008, 8:90 http://www.biomedcentral.com/1472-6750/8/90
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Prior to hybridization total RNA is labelled with biotin
which is later bound to a streptavidin-phycoerythrin con-
jugate. For this purpose the FlexmiR™ MicroRNA Labeling
Kit from Luminex was used. For the comprehensive profil-
ing of 319 microRNAs (FlexmiR™ human microRNA pool,
version 8) 2.5 μg total RNA were labelled, for the analysis
of 10 selected microRNAs (FlexmiR™ Select) 0.5 μg were
labelled following the protocol provided by the manufac-
turer. Subsequent washing, hybridization and analysis of
samples were performed exactly as described in the proto-
cols provided by Luminex.
The system was calibrated using the xMAP™ calibration
control reagents from Luminex following the recommen-
dations of the manufacturer. Every run contained a nega-
tive control for background subtraction (water instead of
RNA) and a positive control (total human brain RNA
from Ambion, provided by Luminex). For data normaliza-
tion the background value for every individual microRNA
bead was subtracted from every corresponding measure-
ment. Subsequently, all corrected mean fluorescence
intensities were normalised to pool 1 using the average
correction factor for the four normalization controls
included in all five pools as recommended by the manu-
facturer (The 319 different microRNA beads are divided
into 5 pools because there are not enough different fluo-
rescence labels available to distinguish more than 70 – 80
beads in a single tube.). These normalised net mean fluo-
rescence intensities were directly compared between
paired samples. All control and normalization beads
(which are identical in the five different pools) were left
out for these comparisons.
microRNA measurement using real time-RT-PCR 
technology
For the measurement of the expression levels of selected
microRNAs (hsa-mir-10b, -21, -145) the real time-RT-
PCR-based detection methodology from ABI (Darmstadt,
Germany) was used. Relative expression levels were calcu-
lated using the constitutively expressed small RNAs
RNU24 and Z-30 as endogenous controls. All primers and
probes were purchased from ABI. cDNA synthesis and
real-time PCR were performed following the protocols
supplied by the manufacturer.
Statistical analysis
The distribution of the microRNA expression data did not
pass the test for normality (α = 0.05) for any specimen.
Therefore, Spearman rank correlation factors were calcu-
lated (two-tailed). For all calculations the software pack-
age GraphPad Prism (version 5.01 for Windows, La Jolla,
CA, USA) was used. p-values < 0.05 were considered sta-
tistically significant.
Abbreviations
FFPE: formalin-fixed paraffin-embedded; LNA: locked
nucleic acid.
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Additional material
Additional file 1
Comparison of expression levels of 319 microRNAs in 5 paired fresh-
frozen and formalin-fixed paraffin-embedded human breast cancer 
specimens. The data provided represent the correlation analysis of the 
microRNA expression levels measured in the paired specimens BrC1 – 
BrC5 (fresh-frozen versus FFPE). The results for BrC1 are also shown in 
Fig. 1.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-8-90-S1.ppt]
Additional file 2
Comparison of expression levels of 319 microRNAs in 5 paired fresh-
frozen and formalin-fixed paraffin-embedded human breast cancer 
specimens leaving out weak signals. The data provided represent the cor-
relation analysis of the microRNA expression levels measured in the paired 
specimens BrC1 – BrC5 (fresh-frozen versus FFPE) leaving out all signals 
below 100 arbitrary units (see main text for further details).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-8-90-S2.ppt]
Additional file 3
Comparison of expression levels of 10 selected microRNAs in BrC1 – 
BrC6. The data provided represent the relative expression levels of 10 
microRNAs reported to be deregulated in human breast cancer (see Table 
1) in the paired specimens BrC1 – BrC6 (fresh-frozen versus FFPE). The 
results for BrC1 are also shown in Fig. 2. The tumours "BrC1 – BrC5" 
were also used for the profiling of 319 microRNAs (see Figure 1 and Addi-
tional file 1).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6750-8-90-S3.ppt]
Additional file 4
Comparison of expression levels of 10 selected microRNAs in BrC7 – 
BrC12. The data provided represent the relative expression levels of 10 
microRNAs reported to be deregulated in human breast cancer (see Table 
1) in the paired specimens BrC7 – BrC12 (fresh-frozen versus FFPE).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
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